Brexpiprazole: A Balance of Risks and Benefits

Area of Science:

• Neuroscience
• Geriatrics
• Pharmacology

Background:

• Alzheimer's disease is the leading cause of dementia, often accompanied by behavioral and psychological symptoms in dementia (BPSD).
• Managing BPSD is complex, with historically limited FDA-approved pharmacological options, leading to off-label medication use.
• Agitation is a common and impactful BPSD, significantly affecting patient prognosis and care.

Purpose of the Study:

• To review the clinical profile of brexpiprazole, focusing on its safety and efficacy in elderly patients.
• To examine the Phase III studies supporting the FDA approval of brexpiprazole for Alzheimer's disease-related agitation.
• To evaluate the potential role and impact of brexpiprazole in the therapeutic landscape for BPSD.

Main Methods:

• Review of clinical trial data from two Phase III studies evaluating brexpiprazole for agitation in Alzheimer's disease dementia.
• Analysis of safety, efficacy, and tolerability data in the target patient population.
• Assessment of brexpiprazole's pharmacological properties, including its affinity for various monoaminergic receptors.

Main Results:

• Two Phase III studies indicated that brexpiprazole is a potentially safe, effective, and well-tolerated treatment for agitation associated with Alzheimer's disease dementia.
• Brexpiprazole demonstrated efficacy in reducing symptoms of agitation in older adults with dementia.
• The drug's safety and tolerability profile in this population was consistent with findings in broader clinical trials.

Conclusions:

• Brexpiprazole represents a novel, FDA-approved therapeutic option for managing agitation in Alzheimer's disease dementia.
• While effective, careful patient assessment is crucial to balance the benefits of brexpiprazole against potential risks.
• This approval offers a new avenue for clinicians managing the complex and multifactorial BPSD.